When the FDA takes action against developers of diagnostic tests, it seems to come primarily during times when new tests are desperately needed. Will Rinehart of the Center for Growth and Opportunity discusses the problem.
Regime Uncertainty for Developers of Coronavirus Tests
Your favorite podcast, in your inbox.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.